|Free Dividend Report|
|Stock Splits Calendar|
|JUNO Stock Split History|
|Preferred Stock Newsletter|
|JUNO Options Chain|
|JUNO Message Board|
JUNO (JUNO) has 1 split in our JUNO split history database. The split for JUNO took place on June 09, 1992. This was a 2 for 1 split, meaning for each share of JUNO owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split.
When a company such as JUNO splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the JUNO split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into JUNO shares, starting with a $10,000 purchase of JUNO, presented on a split-history-adjusted basis factoring in the complete JUNO split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||15.99%|
|Juno Therapeutics is a biopharmaceutical company focused on the treatment of cancer. Co. is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Co.'s CAR and TCR technologies alter T cells ex vivo, so that the T cells can recognize specific proteins on the surface or inside cancer cells or other diseased cells in order to kill those diseased cells. Co.'s product candidates, JCAR017, JCAR014, and JCAR015 utilize CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. According to our JUNO split history records, JUNO has had 1 split.|
|JUNO Split History Table|
|06/09/1992||2 for 1|
|Healthcare Stock Splits|
|JUNO is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:|